JP3911008B2 - レバミピドの改良製造法 - Google Patents
レバミピドの改良製造法 Download PDFInfo
- Publication number
- JP3911008B2 JP3911008B2 JP2006546720A JP2006546720A JP3911008B2 JP 3911008 B2 JP3911008 B2 JP 3911008B2 JP 2006546720 A JP2006546720 A JP 2006546720A JP 2006546720 A JP2006546720 A JP 2006546720A JP 3911008 B2 JP3911008 B2 JP 3911008B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- rebamipide
- formula
- amino acid
- impurity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- ALLWOAVDORUJLA-UHFFFAOYSA-N Rebamipida Chemical compound C=1C(=O)NC2=CC=CC=C2C=1CC(C(=O)O)NC(=O)C1=CC=C(Cl)C=C1 ALLWOAVDORUJLA-UHFFFAOYSA-N 0.000 title description 32
- 229950004535 rebamipide Drugs 0.000 title description 25
- 238000004519 manufacturing process Methods 0.000 title description 5
- -1 amino acid compound Chemical class 0.000 claims description 56
- 239000012535 impurity Substances 0.000 claims description 22
- 150000001875 compounds Chemical class 0.000 claims description 16
- 239000007864 aqueous solution Substances 0.000 claims description 12
- 239000003054 catalyst Substances 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 description 24
- LSAQTAKXZBLFIX-UHFFFAOYSA-N 3-(bromomethyl)-1h-quinolin-2-one Chemical compound C1=CC=C2NC(=O)C(CBr)=CC2=C1 LSAQTAKXZBLFIX-UHFFFAOYSA-N 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- LISFMEBWQUVKPJ-UHFFFAOYSA-N carbostyril Natural products C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 7
- 238000005917 acylation reaction Methods 0.000 description 7
- 238000006722 reduction reaction Methods 0.000 description 7
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- RKIDDEGICSMIJA-UHFFFAOYSA-N 4-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)C=C1 RKIDDEGICSMIJA-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 150000007514 bases Chemical class 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- DYRDKSSFIWVSNM-UHFFFAOYSA-N acetoacetanilide Chemical compound CC(=O)CC(=O)NC1=CC=CC=C1 DYRDKSSFIWVSNM-UHFFFAOYSA-N 0.000 description 3
- 230000010933 acylation Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- QWUOQVLEQGDJAU-UHFFFAOYSA-N 2-amino-3-(6-bromo-2-oxo-1h-quinolin-4-yl)propanoic acid Chemical compound C1=C(Br)C=C2C(CC(N)C(O)=O)=CC(=O)NC2=C1 QWUOQVLEQGDJAU-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 229910000564 Raney nickel Inorganic materials 0.000 description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000005893 bromination reaction Methods 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 229910003002 lithium salt Inorganic materials 0.000 description 2
- 159000000002 lithium salts Chemical class 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 description 1
- NOILRCJONSGSRP-UHFFFAOYSA-N 2-amino-3-(2-oxo-1h-quinolin-4-yl)propanoic acid Chemical compound C1=CC=C2C(CC(N)C(O)=O)=CC(=O)NC2=C1 NOILRCJONSGSRP-UHFFFAOYSA-N 0.000 description 1
- WQACRQUVYBEOFF-UHFFFAOYSA-N 2-amino-3-(2-oxo-1h-quinolin-4-yl)propanoic acid;dihydrate;hydrochloride Chemical compound O.O.Cl.C1=CC=C2C(CC(N)C(O)=O)=CC(=O)NC2=C1 WQACRQUVYBEOFF-UHFFFAOYSA-N 0.000 description 1
- ONIKNECPXCLUHT-UHFFFAOYSA-N 2-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1Cl ONIKNECPXCLUHT-UHFFFAOYSA-N 0.000 description 1
- GWSTUUNCARBYBG-UHFFFAOYSA-N 2-ethylbutanamide;propanedioic acid Chemical compound OC(=O)CC(O)=O.CCC(CC)C(N)=O GWSTUUNCARBYBG-UHFFFAOYSA-N 0.000 description 1
- AGARPHPERRYPRP-UHFFFAOYSA-N 3-bromo-1h-quinolin-2-one Chemical compound C1=CC=C2C=C(Br)C(O)=NC2=C1 AGARPHPERRYPRP-UHFFFAOYSA-N 0.000 description 1
- 206010061164 Gastric mucosal lesion Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 238000003436 Schotten-Baumann reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 238000006798 ring closing metathesis reaction Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
- B01J23/70—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of the iron group metals or copper
- B01J23/74—Iron group metals
- B01J23/755—Nickel
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Materials Engineering (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Description
本発明のさらに他の目的は、ブロモメチルカルボスチリル(2)からの目的のレバミピド(1)を製造する過程で、アシル化直前のカルボスチリルアミノ酸化合物(5)に不純物として混在する6−ブロモカルボスチリルアミノ酸化合物(11)を選択的に還元して有用なカルボスチリルアミノ酸化合物(5)に変換させることによって該不純物を除去し、もって、目的とする高純度のレバミピドをより高収率で製造する方法を提供するものである。
HPLC分析で1.09%の2−アミノ−3−[6−ブロモ−2(1H)キノロン−4−イル]プロピオン酸(式(11)の化合物)を不純物として含む、HPLC分析で純度98.56%の2−アミノ−3−[2(1H)キノロン−4−イル]プロピオン酸一塩酸塩二水和物(式(5)の化合物)10gに、水200ml及び25%の水酸化ナトリウム水溶液10mlを加えて溶解した。この水溶液に50%含水展開ラネーニッケル触媒2gを加えて、2気圧の水素雰囲気下、室温で2時間撹拌した後、触媒を濾過した。尚、2時間撹拌後のHPLC分析で、2−アミノ−3−[6−ブロモ−2(1H)キノロン−4−イル]プロピオン酸(式(11)の化合物)は0.01%、2−アミノ−3−[2(1H)キノロン−4−イル]プロピオン酸(式(5)の化合物)は99.73%であった。次に、触媒を濾過した水溶液に25%の水酸化ナトリウム水溶液10mlを加えた後、4−クロロベンゾイルクロリド10gのアセトン50ml溶液を氷冷下で滴下した。滴下終了後、塩酸酸性とし、析出した結晶を濾取した。得られた結晶を水及びアセトンで洗浄し、約80℃で温風乾燥して、11.7g(収率96.2%、HPLC分析の純度99.60%)のレバミピド(1)を得た。
本発明方法によれば、また、その還元反応における溶媒として水を使用し、比較的短時間のうちに温和な条件で実施できるため、目的化合物の大量合成時における操作が簡単である。さらに、前工程の還元反応終了後に、触媒を濾過して除いた塩基性水溶液のままで、次の段階のアシル化反応に供することができ、目的のレバミピドが高収率で得ることができるため、本発明は、レバミピドの大量合成に極めて有効である。
Claims (1)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004348425 | 2004-12-01 | ||
PCT/JP2005/022412 WO2006059781A1 (en) | 2004-12-01 | 2005-11-30 | Improved process for preparing rebamipide |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007503476A JP2007503476A (ja) | 2007-02-22 |
JP3911008B2 true JP3911008B2 (ja) | 2007-05-09 |
Family
ID=35788485
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006546720A Active JP3911008B2 (ja) | 2004-12-01 | 2005-11-30 | レバミピドの改良製造法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US7718805B2 (ja) |
JP (1) | JP3911008B2 (ja) |
KR (1) | KR101098116B1 (ja) |
CN (1) | CN100537541C (ja) |
HK (1) | HK1099298A1 (ja) |
IL (1) | IL177039A (ja) |
WO (1) | WO2006059781A1 (ja) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101032600B1 (ko) | 2008-08-11 | 2011-05-06 | 동우신테크 주식회사 | 고순도 레바미피드의 제조방법 |
CN101870674B (zh) * | 2009-04-21 | 2012-04-18 | 陕西大生化学科技有限公司 | 改进的瑞巴派特中间体的制备方法 |
CN102174015B (zh) * | 2011-03-07 | 2013-10-16 | 江西同和药业有限责任公司 | 瑞巴派特的精制方法 |
SA113340675B1 (ar) | 2012-06-26 | 2015-08-16 | استيش. كو.، ليمتد | أدوية ريباميبايد تحضيرية جديدة، طريقة تحضيرها واستخدامها |
CN103113294B (zh) * | 2013-03-11 | 2016-04-27 | 浙江远力健药业有限责任公司 | 瑞巴派特的合成方法 |
CN104262346B (zh) * | 2014-09-17 | 2016-06-08 | 广东众生药业股份有限公司 | 一种溴芬酸钠二聚体杂质的制备方法 |
WO2016108319A1 (ko) * | 2015-01-02 | 2016-07-07 | 삼진제약 주식회사 | 신규 레바미피드 전구체의 염 및 이의 용도 |
KR20170094584A (ko) * | 2016-02-11 | 2017-08-21 | 삼진제약주식회사 | 레바미피드 전구체를 포함하는 면역질환 및 대사성질환의 예방 또는 치료를 위한 경구투여용 약제학적 조성물 |
CN113248429A (zh) * | 2021-06-01 | 2021-08-13 | 千辉药业(安徽)有限责任公司 | 一种瑞巴派特原料药的制备方法 |
CN115028579B (zh) * | 2022-06-21 | 2023-07-18 | 福建海西新药创制股份有限公司 | 一种瑞巴派特原料药的合成方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4578381A (en) | 1982-07-05 | 1986-03-25 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
JPS6019767A (ja) * | 1983-07-11 | 1985-01-31 | Otsuka Pharmaceut Co Ltd | カルボスチリル誘導体を有効成分とする抗潰瘍剤 |
JP2820739B2 (ja) | 1989-10-28 | 1998-11-05 | 大塚製薬株式会社 | カルボスチリル誘導体の製造法 |
JP3145468B2 (ja) | 1992-02-27 | 2001-03-12 | マニー株式会社 | かしめ装置に於ける下型の取付構造 |
KR100669823B1 (ko) | 2001-02-20 | 2007-01-17 | 경동제약 주식회사 | 2-(4-클로로벤조일아미노)-3-[2(1h)-퀴놀리논-4-일]프로피온산의 제조방법 및 그 중간체 |
KR100766578B1 (ko) | 2001-12-18 | 2007-10-11 | 동화약품공업주식회사 | 레바미피드의 제조방법 |
KR100520184B1 (ko) | 2002-10-11 | 2005-10-10 | 한미약품 주식회사 | 레바미파이드의 개선된 제조방법 |
-
2005
- 2005-11-30 KR KR1020067015793A patent/KR101098116B1/ko active IP Right Grant
- 2005-11-30 JP JP2006546720A patent/JP3911008B2/ja active Active
- 2005-11-30 US US10/587,509 patent/US7718805B2/en not_active Expired - Fee Related
- 2005-11-30 CN CNB2005800057780A patent/CN100537541C/zh not_active Expired - Fee Related
- 2005-11-30 WO PCT/JP2005/022412 patent/WO2006059781A1/en active Application Filing
-
2006
- 2006-07-23 IL IL177039A patent/IL177039A/en not_active IP Right Cessation
-
2007
- 2007-06-15 HK HK07106485.2A patent/HK1099298A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
JP2007503476A (ja) | 2007-02-22 |
US7718805B2 (en) | 2010-05-18 |
US20070249835A1 (en) | 2007-10-25 |
KR20070085057A (ko) | 2007-08-27 |
IL177039A0 (en) | 2006-12-10 |
CN100537541C (zh) | 2009-09-09 |
WO2006059781A1 (en) | 2006-06-08 |
CN1922145A (zh) | 2007-02-28 |
IL177039A (en) | 2011-03-31 |
KR101098116B1 (ko) | 2011-12-26 |
HK1099298A1 (en) | 2007-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3911008B2 (ja) | レバミピドの改良製造法 | |
JP6948419B2 (ja) | クロマノン誘導体の新規な製造方法 | |
JP6915189B1 (ja) | 高純度2−ナフチルアセトニトリル及びその製造方法 | |
JP2008105970A (ja) | ジヒドロキノリン誘導体の製造方法及びその中間体 | |
JP6228210B2 (ja) | フルボキサミン遊離塩基の精製方法およびそれを用いた高純度フルボキサミンマレイン酸塩の製造方法 | |
WO2016066116A1 (zh) | 阿普斯特的制备方法及其中间体 | |
JP2011098975A (ja) | キラル純n−(トランス−4−イソプロピル−シクロヘキシルカルボニル)−d−フェニルアラニン及びそれらの結晶構造変性体の生成方法 | |
JP2598703B2 (ja) | ブチル3′―(1h―テトラゾール―5―イル)オキサニレートの製造法 | |
JP4545911B2 (ja) | メシル酸カモスタットの製造方法 | |
CA2930089C (en) | Fingolimod hydrochloride process | |
JPWO2003057665A1 (ja) | ベンゼンスルホンアミド誘導体結晶の製造方法、およびその中間体の新規結晶とその製造方法 | |
JP4799085B2 (ja) | 光学活性n置換アミノアシル環状尿素誘導体の製造法 | |
JP2005289835A (ja) | 5−置換−2−アミドフェノールの製造方法 | |
JPWO2005063678A1 (ja) | フェニル酢酸誘導体の製造方法 | |
JPH1129540A (ja) | エステル誘導体の製造方法 | |
JP5010713B2 (ja) | 塩酸カモスタットの製造方法 | |
JP3647915B2 (ja) | 2−アミノ−5−ニトロフェニル酢酸及びその製造方法 | |
JP2007230906A (ja) | N,n−ジメチルカルバモイルメチル4‐ヒドロキシフェニルアセテートの製造法 | |
JP2011051974A (ja) | シベレスタットの合成方法 | |
JPH10101629A (ja) | 光学活性酪酸誘導体の製造方法 | |
KR20090051855A (ko) | 몬테루카스트 사이클로헥실아민 염의 신규한 결정다형 및그의 제조방법 | |
JPH07224058A (ja) | 4−(p−クロロベンジル)−2−(ヘキサハイドロ−1−メチル−1H−アゼピン−4−イル)−1(2H)−フタラジノン又はその塩の製造方法 | |
JPH06157538A (ja) | キノロンカルボン酸類の精製方法 | |
JPH09328473A (ja) | 3,4−ジヒドロカルボスチリルの製造方法 | |
JP2004075616A (ja) | 4−ハロゲノ−2−(4−フルオロフェニルアミノ)−5,6−ジメチルピリミジンの製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060220 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060105 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20060220 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20061228 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070116 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070125 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 3911008 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100202 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130202 Year of fee payment: 6 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160202 Year of fee payment: 9 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |